Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin

被引:29
作者
Chang, MY [1 ]
Jan, MS [1 ]
Won, SJ [1 ]
Liu, HS [1 ]
机构
[1] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan
关键词
D O I
10.1006/bbrc.1998.8911
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study demonstrates that Ha-ras(Val12) oncogene overexpression sensitizes NIH/3T3 fibroblasts to lovastatin (LOV) cytotoxicity. This sensitization is through apoptosis, which was characterized by increasing CPP32 (caspase-3) activity and DNA fragmentation. Bcl-2 overexpression increased the resistance of the Ha-ras transformants to LOV and rescued the cells from apoptosis, further confirming that the LOV-sensitive cells died of apoptosis. Further analysis showed that Ha-ras activity inversely correlated with WAF1 activity. LOV treatment suppressed Ha-ras activity but induced WAF1 activity and disrupted the cell population in G(0)/G(1) and S phases. The Ha-ras transformants expressing either dominant negative Ras(Asn17) or Raf-1(CB4) showed reverted susceptibility to LOV. These data confirm the involvement of Ras and demonstrate that Raf-l signalling is required for LOV-induced cell death. Taken together, the possible action of LOV-induced apoptosis is through suppressing Ha-ras activity and increasing WAF1 activity, which alters cell cycle progression and finally activates suppressed apoptotic pathway in a Fas/Fas-L- and p53-independent fashion. (C) 1998 Academic Press.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 35 条
[1]   Apoptosis: Activate NF-kappa B or die? [J].
Baichwal, VR ;
Baeuerle, PA .
CURRENT BIOLOGY, 1997, 7 (02) :R94-R96
[2]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[3]   SERUM-INDUCED, TPA-INDUCED, AND RAS-INDUCED EXPRESSION FROM AP-1/ETS-DRIVEN PROMOTERS REQUIRES RAF-1 KINASE [J].
BRUDER, JT ;
HEIDECKER, G ;
RAPP, UR .
GENES & DEVELOPMENT, 1992, 6 (04) :545-556
[4]   A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines [J].
Chang, MY ;
Won, SJ ;
Liu, HS .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1997, 123 (02) :91-99
[5]   Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide [J].
Chen, G ;
Shu, JY ;
Stacey, DW .
ONCOGENE, 1997, 15 (14) :1643-1651
[6]   Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine [J].
deSouza, PL ;
Castillo, M ;
Myers, CE .
BRITISH JOURNAL OF CANCER, 1997, 75 (11) :1593-1600
[7]   INHIBITION OF NIH-3T3 CELL-PROLIFERATION BY A MUTANT RAS PROTEIN WITH PREFERENTIAL AFFINITY FOR GDP [J].
FEIG, LA ;
COOPER, GM .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (08) :3235-3243
[8]  
FERNANDEZ A, 1995, ONCOGENE, V10, P769
[9]   APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD [J].
FISHER, DE .
CELL, 1994, 78 (04) :539-542
[10]  
GALANG CK, 1994, ONCOGENE, V9, P2913